Roche, Biosite, Bayer, Inverness And Abbott Acquiring The Major Share Of Point Of Care Testing (POCT

Point-of-care testing allows physicians and medical staff to precisely achieve real-time, lab-quality diagnostic results within minutes rather than hours and enables them to make rapid triage and treatment decisions when diagnosing a patient’s condition or monitoring a treatment response.

According to Goldstein Research, POCT devices contribute 7-8% in the medical device market. Global medical device market in the year 2016 reached USD 315 billion on the back of rapid advancement in medical devices technology with emerging healthcare industry that represents more than USD 1.3 trillion and is growing at the rate of 6.8% across the globe.

The global POCT devices market is segmented based on systems, clinical specialties & diseases, areas of use and end user. On the basis of system POCT devices are categorized into blood gas family, cardiac, diabetes, urinalysis, and informatics. Blood Gas Systems provide test data quickly with minimal operator interaction. Major application areas of POCT devices comprises of self-monitoring; community testing in the pharmacy; general practice; and the emergency department.

Key players in the POCT devices market are Abbott Laboratories, Bayer, Biosite, bioMerieux, Cholestech, Instrumentation Laboratory, Inverness, International Technidyne Corporation, Meridian, Nova Biomedical, Roche and Quidel. With perception of POCT expansion, various market players are actively involved in broaden the product portfolio of next-generation products. For instance, the Shiga Prefecture Industrial Support Center is operating jointly with miscellaneous companies and universities in order to develop a POCT system having potential to deliver sophisticated diagnoses from a single drop of blood. While many joint projects�"involving Immuno Probe, Fukaekasei, Kyushu University, Tokyo Dental College, Panasonic Healthcare, and others�"is occupied in evolving an intraoral bacteriological device suitable for diagnosing periodontal disease. There is an opportunity for new players in the market such as infectious and cardiac areas where modern technologies are probable to acquire the market.

Geographically, German POCT devices industry is almost USD 1.2 billion in 2016.  North America held the largest market share of the global POCT device market owing to huge and increasing addressable patient population base. The US will remain the largest producer and consumer of medical devices, accounting for 26% of the global POCT device market. Asia Pacific is the opportunistic market for POCT device manufacturers. In Asia, LamdaGen Taiwan will commercialize a number of powerful, single-step, rapid and precisely quantitated POCT diagnostics with sensitivities into the low to sub-femtomolar range using a single sample drop.